Cargando...
Long-Term Use of Ruxolitinib in an AML Patient with Posttransplant Steroid Refractory GVHD
Ruxolitinib has become a new therapeutic option for steroid refractory graft-versus-host disease (srGVHD), with a substantial remission rate. Its anti-inflammatory properties by blocking interleukin pathways have made it a novel therapeutic approach to inflammatory disease processes, such as GVHD. T...
Gardado en:
| Publicado en: | Case Rep Oncol Med |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Hindawi
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7166298/ https://ncbi.nlm.nih.gov/pubmed/32318300 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2020/4936846 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|